Inclusion Criteria:

- The patients > 18 years of age

- Histologically or cytologically proven breast cancer

- Receiving CEF chemotherapy cycles presently or in the past

- The patients who will give informed consent to participate in the study

- Patients must have sufficient organ and marrow function

- Stage 1 neuropathy, subclinical neuropathy, surgery induced neuropathy

Exclusion Criteria:

- Pregnancy

- Clinical/biochemical severe liver failure

- Clinical/biochemical severe renal dysfunction

- Refusal to participate in the study

- Patients who have received prior chemotherapy with paclitaxel.

- Patients who have neuropathy due to any known systemic or metabolic causes like
diabetes, leprosy, nutritional deficiency induced (vit. B12) etc